Date: 2017-04-19
Type of information: Nomination
Compound: members of board of directors
Company: Transgene (France)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 19, 2017, Transgene announced the evolution and reinforcement of its board of directors. Two new independent board members, Marie Landel and Maya Said, have been appointed.
- Marie Landel founded Marie Landel & Associates, now Axcelia Partners, a consultancy based in Cambridge (Massachusetts) specialized in advising European companies on the creation and development of US subsidiaries. Marie has significant experience supporting French and European biotechnology companies in the United States. In her 27 years of practice, she has built an extensive network in the financial community focused on this sector. Marie is a French CPA (Expert-comptable), and she holds an MBA from the European Business School (Paris, Frankfurt and London).
Marie also sits on the Boards of TxCell, Safe Orthopaedics and Cellnovo.
- Maya Said brings more than 15 years of international strategic, operational and research experience working across academia and the healthcare industry. Previously, she was Vice-President, Senior Global Head of Oncology Policy and Market Access at Novartis, and Vice President, Head of Strategy, Science Policy & External Innovation, Global R&D at Sanofi. Her career started within the HealthCare and Strategy practice of The Boston Consulting Group (BCG).
Maya has a Ph.D. in Electrical Engineering, Computer Science & Systems Biology from the Massachusetts Institute of Technology (MIT), as well as two Master’s degrees in Electrical Engineering & Computer Science and in Biology. She has also studied finance and healthcare organizational systems at the Harvard Business School.
Financial terms:
Latest news:
Is general: Yes
